FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nadia Rupniak

Research Profile

Chemicals & Drugs

Living Beings

Activities & Behaviors

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Laura C Meurer; Paul E Finke; Karen Owens; Nancy N Tsou; Richard G Ball; Sander G Mills; Malcolm MacCoss; Sharon Sadowski; Margaret A Cascieri; Kwei-Lan Tsao; Gary G Chicchi; Linda A Egger; Silvi Luell; Joseph M Metzger; D Euan MacIntyre; Nadia M J Rupniak; Angela R Williams; Richard Hargreaves
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
Michael Rigby; Ruth O'Donnell; Nadia M J Rupniak
Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.
Marieke G C van der Hart; Gabriel de Biurrun; Boldizsár Czéh; Nadia M J Rupniak; Johan A Den Boer; Eberhard Fuchs
Chronic psychosocial stress in tree shrews: effect of the substance P (NK1 receptor) antagonist L-760735 and clomipramine on endocrine and behavioral parameters.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nadia Rupniak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Laura C Meurer; Paul E Finke; Karen Owens; Nancy N Tsou; Richard G Ball; Sander G Mills; Malcolm MacCoss; Sharon Sadowski; Margaret A Cascieri; Kwei-Lan Tsao; Gary G Chicchi; Linda A Egger; Silvi Luell; Joseph M Metzger; D Euan MacIntyre; Nadia M J Rupniak; Angela R Williams; Richard Hargreaves
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
Bioorganic & medicinal chemistry letters 2006;16(17):4504-11.
2005: Michael Rigby; Ruth O'Donnell; Nadia M J Rupniak
Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.
The Journal of comparative neurology 2005;490(4):335-53.
2005: Marieke G C van der Hart; Gabriel de Biurrun; Boldizsár Czéh; Nadia M J Rupniak; Johan A Den Boer; Eberhard Fuchs
Chronic psychosocial stress in tree shrews: effect of the substance P (NK1 receptor) antagonist L-760735 and clomipramine on endocrine and behavioral parameters.
Psychopharmacology 2005;181(2):207-16.
2005: Martin R Guscott; Linda J Bristow; Karen L Hadingham; Thomas W Rosahl; Margaret S Beer; Josephine A Stanton; Frances A Bromidge; Andrew P Owens; Ian T Huscroft; Janice Myers; Nadia M J Rupniak; Smita Patel; Paul J Whiting; Peter H Hutson; Kevin C F Fone; S M Biello; Janusz J Kulagowski; George McAllister
Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.
Neuropharmacology 2005;48(4):492-502.
2004: Nadia M J Rupniak
Neural plasticity and the promise of novel pharmacotherapies for depression. Commentary on Fuchs et al., examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews.
Behavioural pharmacology 2004;15(5-6):369-71.
2004: Paul C Guest; Michael R Knowles; Sylvain Molon-Noblot; Kamran Salim; David Smith; Fraser Murray; Philippe Laroque; Stephen P Hunt; Carmen De Felipe; Nadia M J Rupniak; George McAllister
Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling.
Brain research 2004;1002(1-2):1-10.
2004: Karl Ebner; Nadia M J Rupniak; Alois Saria; Nicolas Singewald
Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(12):4280-5.
2003: Andrew Holmes; Markus Heilig; Nadia M J Rupniak; Thomas Steckler; Guy Griebel
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
Trends in pharmacological sciences 2003;24(11):580-8.
2003: Sara Morcuende; Christopher A Gadd; Marco Peters; Andrew Moss; Elizabeth A Harris; Anne Sheasby; Amy S Fisher; Carmen De Felipe; Patrick W Mantyh; Nadia M J Rupniak; peter giese; Stephen P Hunt
Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice.
The European journal of neuroscience 2003;18(7):1828-36.
2003: Nadia M J Rupniak; A Fisher; Susan Boyce; D Clarke; A Pike; desmond oconnor; A Watt
P-Glycoprotein efflux reduces the brain concentration of the substance P (NK1 receptor) antagonists SR140333 and GR205171: a comparative study using mdr1a-/- and mdr1a+/+ mice.
Behavioural pharmacology 2003;14(5-6):457-63.
2003: Nadia M J Rupniak
Animal models of depression: challenges from a drug development perspective.
Behavioural pharmacology 2003;14(5-6):385-90.
2003: Nadia M J Rupniak; Emma J Carlson; Sara Shepheard; Graham Bentley; Angela R Williams; Alastair Hill; Christopher J Swain; Sander G Mills; Jerry Di Salvo; Ruth Kilburn; Margaret A Cascieri; Marc M Kurtz; Kwei-Lan Tsao; Sandra L Gould; Gary G Chicchi
Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608.
Neuropharmacology 2003;45(2):231-41.
2003: Nadia M J Rupniak; Janine K Webb; A Fisher; David Smith; Susan Boyce
The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils.
Neuropharmacology 2003;44(4):516-23.
2002: Brian J Williams; Margaret A Cascieri; Gary G Chicchi; Timothy Harrison; Andrew P Owens; Simon N Owen; Nadia M J Rupniak; David F Tattersall; Angela Williams; Christopher J Swain
Spirocyclic NK(1) antagonists II: [4.5]-spiroethers.
Bioorganic & medicinal chemistry letters 2002;12(19):2719-22.
2002: Nadia M J Rupniak
Analysing mice. Commentary on Stephens et al. 'Studying the neurobiology of stimulant and alcohol abuse and dependence in genetically manipulated mice'.
Behavioural pharmacology 2002;13(5-6):353-4.
2002: Rachel K Conley; Michael J Cumberbatch; Glenn S Mason; David J Williamson; Timothy Harrison; Karen Locker; Christopher J Swain; Karen A Maubach; Ruth O'Donnell; Michael Rigby; Louise Hewson; David Smith; Nadia M J Rupniak
Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(17):7730-6.
2002: Nadia M J Rupniak
New insights into the antidepressant actions of substance P (NK1 receptor) antagonists.
Canadian journal of physiology and pharmacology 2002;80(5):489-94.
2002: Glenn S Mason; Michael J Cumberbatch; Raymond G Hill; Nadia M J Rupniak
The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits.
Canadian journal of physiology and pharmacology 2002;80(4):264-8.
2002: Nadia M J Rupniak
Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
Current opinion in investigational drugs (London, England : 2000) 2002;3(2):257-61.
2002: Karen A Maubach; Karine Martin; Gary G Chicchi; Timothy Harrison; Alan Wheeldon; Christopher J Swain; Michael J Cumberbatch; Nadia M J Rupniak; Guy R Seabrook
Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.
Neuroscience 2002;109(3):609-17.
2001: Timothy Harrison; Andrew P Owens; Brian J Williams; Christopher J Swain; A Williams; Emma J Carlson; Wayne Rycroft; F David Tattersall; Margaret A Cascieri; Gary G Chicchi; Sharon Sadowski; Nadia M J Rupniak; Richard Hargreaves
An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
Journal of medicinal chemistry 2001;44(24):4296-9.
2001: S Boyce; Nadia M J Rupniak; M J Steventon; S D Iversen
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.
Neurology 2001;57(10 Suppl 3):S27-33.
2001: Nadia M J Rupniak; Emma J Carlson; Janine K Webb; Timothy Harrison; R D Porsolt; S Roux; Carmen De Felipe; Stephen P Hunt; B Oates; Alan Wheeldon
Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs.
Behavioural pharmacology 2001;12(6-7):497-508.
2001: Nicolas Froger; Alain M Gardier; Rosario Moratalla; Israel Alberti; I Lena; Claudette Boni; Carmen De Felipe; Nadia M J Rupniak; Stephen P Hunt; Christian Jacquot; Michel Hamon; Laurence Lanfumey
5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(20):8188-97.
2001: Susan Boyce; David Smith; E Carlson; Louise Hewson; Michael Rigby; Ruth O'Donnell; Timothy Harrison; Nadia M J Rupniak
Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs.
Neuropharmacology 2001;41(1):130-7.
2000: Nadia M J Rupniak; E C Carlson; Timothy Harrison; B Oates; Eileen M Seward; S Owen; Carmen De Felipe; S Hunt; Alan Wheeldon
Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
Neuropharmacology 2000;39(8):1413-21.
2000: Susan Boyce; Janine K Webb; Sara Shepheard; Michael G N Russell; Raymond G Hill; Nadia M J Rupniak
Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
Pain 2000;85(3):443-50.
2000: Jeffrey J Hale; Sander G Mills; Malcolm MacCoss; C P Dorn; Paul E Finke; Richard J Budhu; R A Reamer; Su-Er W Huskey; D Luffer-Atlas; Brian J Dean; Erin McGowan; William P Feeney; Shuet-Hing Lee Chiu; Margaret A Cascieri; Gary G Chicchi; Marc M Kurtz; Sharon Sadowski; E Ber; F David Tattersall; Nadia M J Rupniak; Angela R Williams; Wayne Rycroft; Richard Hargreaves; Joseph M Metzger; D Euan MacIntyre
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Journal of medicinal chemistry 2000;43(6):1234-41.
1999: Nadia M J Rupniak; M S Kramer
Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists.
Trends in pharmacological sciences 1999;20(12):485-90.
1999: DW Smith; Louise Hewson; P Fuller; Angela R Williams; Alan Wheeldon; Nadia M J Rupniak
The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala.
Brain research 1999;848(1-2):90-5.
1999: Karen A Maubach; Nadia M J Rupniak; M S Kramer; Raymond G Hill
Novel strategies for pharmacotherapy of depression.
Current opinion in chemical biology 1999;3(4):481-8.
1999: Susan Boyce; A Wyatt; Janine K Webb; Ruth O'Donnell; Glenn Mason; Michael Rigby; DJ Sirinathsinghji; Raymond G Hill; Nadia M J Rupniak
Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.
Neuropharmacology 1999;38(5):611-23.
1999: Susan Boyce; Janine K Webb; E Carlson; Nadia M J Rupniak; Raymond G Hill; J E Martin
Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl.
Experimental neurology 1999;155(1):49-58.
1998: Michael J Cumberbatch; E Carlson; A Wyatt; Susan Boyce; Raymond G Hill; Nadia M J Rupniak
Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats.
Neuropharmacology 1998;37(12):1535-43.
1998: Jeffrey J Hale; Sander G Mills; Malcolm MacCoss; Paul E Finke; Margaret A Cascieri; Sharon Sadowski; E Ber; Gary G Chicchi; Marc M Kurtz; J Metzger; G Eiermann; Nancy N Tsou; F David Tattersall; Nadia M J Rupniak; Angela R Williams; Wayne Rycroft; Richard Hargreaves; D Euan MacIntyre
Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Journal of medicinal chemistry 1998;41(23):4607-14.
1998: Mark S Kramer; N Cutler; J Feighner; R Shrivastava; J Carman; J J Sramek; Scott A Reines; G Liu; Duane Snavely; E Wyatt-Knowles; Jeffrey J Hale; Sander G Mills; Malcolm MacCoss; Christopher J Swain; Timothy Harrison; Raymond G Hill; Franz Hefti; Edward M Scolnick; Margaret A Cascieri; Gary G Chicchi; Sharon Sadowski; Angela R Williams; Louise Hewson; David Smith; Emma J Carlson; Richard Hargreaves; Nadia M J Rupniak
Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Science (New York, N.Y.) 1998;281(5383):1640-5.
1997: Smita Patel; S Freedman; Kerry L Chapman; F Emms; AE Fletcher; M Knowles; Rose Marwood; George McAllister; Janice Myers; Neil R Curtis; Janusz J Kulagowski; Paul D Leeson; Mark P Ridgill; M Graham; S Matheson; D Rathbone; Alan P Watt; Linda J Bristow; Nadia M J Rupniak; E Baskin; Joseph J Lynch; C Ian Ragan
Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
The Journal of pharmacology and experimental therapeutics 1997;283(2):636-47.
1997: Nadia M J Rupniak; S J Tye; mark field
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys.
Psychopharmacology 1997;131(4):406-10.
1997: Nadia M J Rupniak; F David Tattersall; Angela R Williams; Wayne Rycroft; Emma J Carlson; Margaret A Cascieri; Sharon Sadowski; E Ber; Jeffrey J Hale; Sander G Mills; Malcolm MacCoss; Eileen M Seward; Ian T Huscroft; S Owen; Christopher J Swain; Raymond G Hill; Richard Hargreaves
In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
European journal of pharmacology 1997;326(2-3):201-9.
1997: Nadia M J Rupniak; Susan Boyce; Janine K Webb; Angela R Williams; Emma J Carlson; Raymond G Hill; J A Borkowski; J F Hess
Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice.
Pain 1997;71(1):89-97.
1996: Nadia M J Rupniak; E Carlson; Susan Boyce; J K Webb; Raymond G Hill
Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils.
Pain 1996;67(1):189-95.
1996: Susan Boyce; Nadia M J Rupniak; Emma J Carlson; J Webb; J A Borkowski; J Fred Hess; Catherine D Strader; Raymond G Hill
Nociception and inflammatory hyperalgesia in B2 bradykinin receptor knockout mice.
Immunopharmacology 1996;33(1-3):333-5.
1996: J K Webb; Nadia M J Rupniak; S Boyce
Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide.
Regulatory peptides 1996;61(1):71-6.
1995: Gerard R Dawson; Nadia M J Rupniak; S D Iversen; R Curnow; S Tye; K J Stanhope; mark david tricklebank
Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.
Psychopharmacology 1995;121(1):109-17.
1995: Nadia M J Rupniak; J K Webb; Angela R Williams; E Carlson; Susan Boyce; Raymond G Hill
Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils.
British journal of pharmacology 1995;116(2):1937-43.
1994: Nadia M J Rupniak; Smita Patel; Rose Marwood; J Webb; John R Traynor; J Elliott; S B Freedman; S R Fletcher; Raymond G Hill
Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity.
British journal of pharmacology 1994;113(4):1487-93.
1994: Nadia M J Rupniak; Angela R Williams
Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists.
European journal of pharmacology 1994;265(3):179-83.
1994: Nadia M J Rupniak; A Jackson
Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs.
European journal of pharmacology 1994;262(1-2):171-5.
1993: Nadia M J Rupniak; Susan Boyce; Angela R Williams; G Cook; Jenny Longmore; Guy R Seabrook; M Caeser; S D Iversen; Raymond G Hill
Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580.
British journal of pharmacology 1993;110(4):1607-13.
1993: Nadia M J Rupniak; L Schaffer; Peter K S Siegl; S D Iversen
Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys.
Neuropeptides 1993;25(2):115-9.
1993: Nadia M J Rupniak; Susan Boyce; S Tye; G Cook; S D Iversen
Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primates.
Pharmacology, biochemistry, and behavior 1993;44(1):153-6.
1992: Nadia M J Rupniak; Susan Boyce; M Steventon; S D Iversen
Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.
Clinical neuropharmacology 1992;15(4):307-9.
1992: Nadia M J Rupniak; Susan Boyce; M J Steventon; S D Iversen; CD Marsden
Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
Annals of neurology 1992;32(1):103-5.
1992: Nadia M J Rupniak; S J Tye; S D Iversen
Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates.
Journal of the neurological sciences 1992;110(1-2):222-7.
1992: L Iversen; A C Foster; Raymond G Hill; S D Iversen; J A Kemp; Paul D Leeson; Nadia M J Rupniak; KL Saywell; mark david tricklebank; B J Williams
Neurotoxin-related research: from the laboratory to the clinic.
Annals of the New York Academy of Sciences 1992;648():207-18.
1992: Nadia M J Rupniak; S J Tye; C Brazell; A Heald; S D Iversen; P G Pagella
Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Journal of the neurological sciences 1992;107(2):246-9.
1992: Nadia M J Rupniak; M Duchnowski; S J Tye; G Cook; S D Iversen
Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencyclidine in primates.
Life sciences 1992;50(25):1959-62.
1991: K Lam; Nadia M J Rupniak; S D Iversen
Use of a grooming and foraging substrate to reduce cage stereotypies in macaques.
Journal of medical primatology 1991;20(3):104-9.
1991: Nadia M J Rupniak; N A Samson; S J Tye; mark field; S D Iversen
Evidence against a specific effect of cholinergic drugs on spatial memory in primates.
Behavioural brain research 1991;43(1):1-6.
1991: Susan Boyce; Nadia M J Rupniak; M J Steventon; G Cook; S D Iversen
Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates.
Behavioural brain research 1991;42(2):115-21.
1991: Nadia M J Rupniak; N A Samson; M J Steventon; S D Iversen
Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeys.
Life sciences 1991;48(9):893-9.
1990: Nadia M J Rupniak; mark field; N A Samson; M J Steventon; S D Iversen
Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models.
Neurobiology of aging 1990;11(6):609-13.
1990: mark david tricklebank; T Honoré; S D Iversen; J A Kemp; Antony Knight; George R Marshall; Nadia M J Rupniak; L Singh; S Tye; F Watjen
The pharmacological properties of the imidazobenzodiazepine, FG 8205, a novel partial agonist at the benzodiazepine receptor.
British journal of pharmacology 1990;101(3):753-61.
1990: Susan Boyce; Nadia M J Rupniak; M J Steventon; S D Iversen
Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.
Clinical neuropharmacology 1990;13(5):448-58.
1990: Susan Boyce; Nadia M J Rupniak; S Tye; M J Steventon; S D Iversen
Modulatory role for CCK-B antagonists in Parkinson's disease.
Clinical neuropharmacology 1990;13(4):339-47.
1990: Nadia M J Rupniak; Susan Boyce; M J Steventon; S D Iversen
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.
Journal of neurology, neurosurgery, and psychiatry 1990;53(7):622-3.
1990: Susan Boyce; Nadia M J Rupniak; M J Steventon; S D Iversen
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Neurology 1990;40(6):927-33.
1990: Susan Boyce; Nadia M J Rupniak; M Steventon; S D Iversen
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Neurology 1990;40(4):717-8.
1990: Susan Boyce; Nadia M J Rupniak; M J Steventon; S D Iversen
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
Psychopharmacology 1990;102(1):21-7.
1990: Nadia M J Rupniak; S J Tye; M J Steventon; Susan Boyce; S D Iversen
Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
Movement disorders : official journal of the Movement Disorder Society 1990;5(4):314-8.
1990: Nadia M J Rupniak; S J Tye; S D Iversen
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Psychopharmacology 1990;102(3):325-8.
1989: S J Tye; Nadia M J Rupniak; T Naruse; M Miyaji; S D Iversen
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Clinical neuropharmacology 1989;12(5):393-403.
1989: Nadia M J Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; Elizabeth Hand; S D Iversen; S M Stahl
Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
Neurology 1989;39(3):329-35.
1989: Nadia M J Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; S D Iversen; S M Stahl
Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.
Journal of neurology, neurosurgery, and psychiatry 1989;52(2):289-90.
1989: Nadia M J Rupniak; M J Steventon; mark field; C A Jennings; S D Iversen
Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.
Psychopharmacology 1989;99(2):189-95.
1988: C E Bryant; Nadia M J Rupniak; S D Iversen
Effects of different environmental enrichment devices on cage stereotypies and autoaggression in captive cynomolgus monkeys.
Journal of medical primatology 1988;17(5):257-69.